MerryLife Biomedical

MerryLife Biomedical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of next-generation cell therapies for cancer and autoimmune diseases. The company focuses on advancing Chimeric Antigen Receptor T-cell (CAR-T) and Natural Killer (NK) cell technologies, with a particular emphasis on overcoming the limitations of current autologous treatments. Their pipeline includes several candidates targeting hematological malignancies and solid tumors, utilizing proprietary platforms to enhance cell persistence and efficacy. MerryLife aims to provide more accessible and effective immunotherapy options through both autologous and universal 'off-the-shelf' approaches. The company is actively conducting early-phase clinical trials in China to validate its lead candidates.